FATE - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Fate Therapeutics Second Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Fate webcast at fatetherapeutics.com.

As a reminder, today's call is being recorded. I would now like to introduce Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Scott Wolchko

you. Thank thanks XXXX us financial and Therapeutics the for quarter second results everyone afternoon for joining Fate Good call. found results, Shortly today, after website can under these of we Time Investors be which issued a Press Media X press release our PM section on the Eastern & Releases. with

Media for Financial quarter and on found can June our section our XXXX under XX, & website of addition, In the was Form Information. be the XX-Q ended filed thereafter Investors shortly

of reflect statements underlying Fate as Therapeutics forward-looking any events, the Undue these date placed well Form disclaims which Except these as the like today, would our of company's required should the information, filings, I circumstances call Before remind statements everyone with the by SEC Private risk statements was only June begin, we that in actual SEC to law, from by after statements responses market disclaimer they in be statements, Safe conference to release Reform differ materially XXXX for except or the to of factors in filed the forward-looking on Securities forward-looking to the such today. historical on made under and that the quarter can provisions are press forward-looking of not that for this change. included the facts XX, cause Litigation facts, the Harbor Act made, These on are as to statements the may the future XX-Q management obligation and of and XXXX. forward-looking those results forward-looking as issued close Please statements ended statements. circumstances. see reliance update speak as involve earnings statement company's uncertainties risks questions

our Joining objectives which the key Today, execution the Dr. of after progress Chief Shoemaker, across to discussion. six Dan call second today we review will our our up me our Storgard, will further I open the and am questions Medical our the XXXX Scientific Chris operational for Officer. over call quarter, months and Chief and Officer; highlight first Dr. with are results financial on I pleased the business. against XXXX very

positioned the months out ProTmune, graft, to read and well next next-generation are NKXXX. to several hematopoietic in our for data clinical We for both continue cell

NK Our first adaptive immunotherapy. in class cancer memory cell

the the iPSC cell application Additionally, FTXXX a FDA IND poised of in with therapies. made universal utilizes iPSC immunotherapy off submission strategic of NK the are usher of renewable in now toward cancer landmark for to that I achieving cell master development master line the shelf important mass believe immune with the cancer for Overall, patients products. One of disorders. strides our line, this we of past to of lives first-to-kind quarter operational clinical derived from the production our we era new a mission and and transforming sell delivery

up to significant trial Turning double subjects of X intend undergoing and matched to hematopoietic the of malignancies unrelated XX first Phase have transplantation. hematologic ongoing and adult enrollment ProTmune which our treat in ProTmune, controlled randomized we to study, blinded subject seen cell protect we clinical with donor acceleration

severe as intend Phase The subjects. studies of we in clinical day X PROTECT as to annual at endpoint. on Annual of year for present undergoing the chronic At the March. best the at on cumulative ASBMT alive been that We the from successful XXX without second by -term at cancer ASH and believe X of moderate on meeting active protect at the in were X secondary presentation or enthusiasm acute to PROTECT the ProTmune XXXX, incidence data for HCT. Meeting Phase following peripheral additional to investigator the ongoing XXXX, relapse attribute of cancer X relapse We continuing has of secondary subjects and stage following ProTmune GvHD, a defines the endpoint the a acceleration data XX is data cancer ASH the total meetings death we a in conventional Phase Meeting ProTmune That subjects HCT. We're long to the Phase endpoint. December and graft, administered these primary X patients presented the state stage including encouraging. data The and well follow either Freedom of without our this from study treated year GvHD. During captures ideal administered clinical blood Phase of mobilized one protect protect subjects in that to outcome one initial bringing relapse from Annual the study total X GvHD XX. number these

We natural adoptive milestones of and comprised cell also achieved NKXXX, several within clinical memory first-in-class Allergenic our immunotherapy cancer donor-derived killer K-cells.

of We FDA-approved looking studies, subjects dose AML. significant time, refractory or of At reported tumor no to in been subjects NKXXX burden are treatment cancer recurrent or have studies the relapsed related for antibody there at have toxicities including neurotoxicity. in no therapy. DIMENSION treatment syndrome including all of all events release of monoclonal cytokine heavily treatment limiting the APOLLO approved some advanced have cases clinical and each this NKXXX, no for treated have the Voyage three experimental with in enrollment combination options. these other of for of the In ovarian tumors NKXXX. three three GvHD, with solid trials time therapies across reported including pretreated of and treatment of

at a A. am Charles also and leading disease APOLLO clinical planned with investor research disclosed in to that an this enrolled in Society November day the cancer of as event study has Immunotherapy that free DIMENSION A enrollment study. state the review subject. morphologic center along we center that added have initial biological data a leukemia top tumor NKXXX. of pleased administration a we with the NKXXX with Phase its of the host the new has achieved Voyage evidence shrinkage in at and second Center of NKXXX. XXXX, of I to that XX for our in pioneer a development patients to single NKXXX following products the company X clinical X for for to investigators Baylor announce our study subject operational already objective XX, Cancer the from day our At studies class second in Additionally, in subject anti-tumor observations observed stable previously have Dallas, Cancer is and for XXXX activity achieved cancer. cell Sammons of first we been of

first human mass clinical of and shelf pluripotent in mastered-induced of products extensively IPSC cell initiate are cell to use patients delivered an the groundbreaking uniformly manufacture We and be and are made NK T-cell products trials master stem that produced enables to of in are engineered the characterized seeking The can homogeneous using that off and in manner. lines. lines composition,

last Drug XX the for Within application investigational Administration FTXXX. days, drug the we Food landmark a and new to U.S. submitted

at that The The to believe a platform. for off initially shelf rescue the our product non-clinical study model. The of NK-cell a inhibitors. The resistant CMC an FTXXX supported from pilot first two toxicity as dose product runs. of study the tumorgenesity demonstrated universal is IND patients multi-dose We evaluated therapy animal manufacturing in well emerging our and was FTXXX by strong. to different We package which results GLP is supported are data successful FTXXX develop intend that data levels checkpoint X tolerated. by administration iPSC

of cell shelf of no that allowance IPSC FTXXX Notably, XX by period. were iPS first cell FDA, of fueled an of it working product. cell believe therapy clinical era knowledge this tumors, FDA There as the IND undergoing in evidence in to be drive application. Specifically, the take derive including producing milestone for administration dopaminergic in with initiate no derived not days. using certainly United for just company, through investigation to iPS kind the disease first uses were us standard honored as were uncommon be our are the therapies FTXXX. of we a There FTXXX the therapy iPS of trials to FDA, or we the cardiac past application Japan, two investigation applications the in to source IND for hematology with engagement first iPS paradigm off the master We excited are are transformative powerful. for the the human were muscle would kind an in as upon derived allowance this the to parameters. FTXXX. failure. for adverse The original line cells review there heart of an and is the IND One already and months. IND iPS pioneer a cell allowance that another or FTXXX is There beyond and is of our related XX several extend is related Similarly, FDA our first new to very investigation using clinical it for It masses clinical prepared To were probably renewable Parkinson's than FDA cell events derived a is observations related clinical entire application changes no at review couple well no allowed --cell of progenitors in The IND to day States. our gained therapy. animals the in submitted and longer there mortality application FDA administered clinical knowledge, of the chemistry

us of the CDXX NK FTXXX, successfully copy non-cleavable characterized variation site From FTXXX, candidates integration CDXX clone provides In the from selected and detailed the As iPSC we producing a it for Gino. single the uniformly and also genomics for of roadmap emerging second the quarter development help express of off-the-shelf in high number bank master are clinical additional transgene universal our which which this stability, a product clone, initiate XXXX, product product our cell made exact we for platform. cell iPSC the receptor. iPSC affinity generated in FC second single to for extensively

study Additionally, in initiated GLP toxicity we tumorgenesity FTXXX. for

with for a eliminate completely development Sadelain milestones. kind of submission. rather under is end of by from the the IND FTXXX, locus. Sloan of XXXX TCR with to the to of guided a the FTXXX to We payment and FTXXX product off-the believe engineering in development the quarter our and FTXXX research expect application a We free engineering an of the the California expect to single shelf a the under for would alloreactive Dr. TRAC is is a precisely XXXX, iPSC T-cell of and be the of interactions of of by which milestone our current insert immunotherapies. the CAR targeting expression Kettering, derived IND ensures universal iPS is clone, institute connection Michel the uniform the that expression of to T-cells than I exclusive of the receptor in IND T-cell $X.X that batch will the derived FDA during CDXX for progress, Memorial potency. product T-cell and first clone highlight primary single cell our T-cell its timing enhanced and collaboration a FTXXX large car receive these candidate, best-in-class in our also engineer at our of CAR each achievement like submission preclinical drug submit iPSC has completely medicine, approach final the for third specific million aim regenerative with from We into

license XXXX, agreement Kettering, The shelf of development quarter relating immunotherapies Memorial conventional inventions, field. off FTXXX. to the Sadelain, potency, portfolio expanded of we Dr. certain property second intellectual newly novel are of CAR covers further therapeutic existing the today as to including our CAR the to with by constructs, widely CAR recent T-cell enable T-cell During Sloan improved use compared with constructs CAR in licensed that made

CAR these constructs, activity a T-Cells preclinical the of functionality and in specific significantly We anti-tumor target have derived assess CAR and and iPS incorporating constructs noble CAR CAR these novel that models. specificity identified improves properties evaluated construct

characterize of making we for the second development half the with FDA to of engage cell master the Dr. to pre-INP Sadelain iPSC clone single a the XXXX. to XXXX, clinical bank select During in FTXXX, partnership plan and meeting FDA we and discuss expect in the

pipeline highlight our Finally, I'm Annual to submitted and off-the-shelf cell hold candidates. to at and Meeting investor plan presentation we, covering universal with collaborators we ASH for cancer along and cell abstracts announce the that T at product immunotherapy to our event ASH an XXXX X iPSC-derived pleased NK our

compared as million, million, per for common of the Turning $XX.X or same share ended our second June or to a reported share, period. net loss Fate a results financial of XX, the $X.X to quarter for per common $X.XX $X.XX loss XXXX. Therapeutics net

second expense Memorial $X.X of the million net additional property of Kettering. The with loss included associated a onetime from in-license Sloan quarter intellectual

loss development ended share. both in quarter Research activities Excluding increase an from per for the the clinical as Revenue same $X.X expenses quarter generated the administrative was development primarily million of XXXX and to this second increase application. expense NKXXX $X.XX The quarter well was was to with additional expenses for in-license of compared XXXX. year. second research XXXX from second period common regulatory support with and intellectual or quarter were with as increase Revenue attributable periods compared Juno XXXX, primarily submission expenses attributable the for strategic last $X.X for of FTXXX R&D the our our expense, XXXX, of was our associated in million expenses of G&A manufacturing the million for Therapeutics. million, our General onetime for last Sloan associated million was the $XX.X quarter for of $X employee the $XX.X The associated for second operating net $X.X were onetime to same from and adjusting million, June with $XX.X XXXX advisory property as proceeds compensation general funding the IND XX, million of second $X.X to period collaboration equivalents year. expenses and quarter preferred the $X.X in million growth and Memorial million million second and the were in Kettering, the XXXX, stock quarter of the million. investments XX.X well of Common outstanding based compared and was shares, of approximately At increase to $XX approximately adjusted outstanding cash, I'd well and for five conditions. the to $X.X for quarter approximately for including expense stock and fees, is second of under common approximately to quarter our approximately which intellectual certain with of as each $X.X Therapeutics for stock of collaborators. X.X after $XXX,XXX Total million. Juno headcount every the was end million cash of approximately thank research employee expenses compensation, like the of of in related of first XXXX. into of shares, of million increased and of Fate In XXXX represents the expense as operating $XX.X expenses. million short-term convertible as were an as second onetime property Total convertible each closing, shares expenses Therapeutics, legal of stock

innovative Your era. a field creativity, of progressed spirit commitment has our to the therapy new cell and to mission unrelenting

questions. call our an up patients development with And transform clinical We of I'd are disorders. working immune to immuno be FDA open and part like important of honored to the derived IPS with cancer to excited pioneer and the therapies as to of the lives that, mission cellular the to with

Operator

Thank Instructions] you. [Operator

with question Jaffray. comes Piper first Our from Ted Tenthoff

now Your is open. line

Ted Tenthoff

IND Great, the much I very on and very and questions exciting. progress filing, may. thank if Two you all congrats

bit you're Firstly, iPSC to think little little caution Scott Is take filing potential this to for going take going filing. plans, foreseeing IND FDA think the as up. time I right do have that with bit a you may what are follow longer of kind then ever I longer, a respect is What CMC safety in review quick to this the first more a issues, on? items you be and to

Scott Wolchko

the IPS creation line the an cell And the Master on from discussing meeting, reprogramming that cell at really of we derived to FDA an two pre-IND with focusing NK in feel pre-IND Sure, time second have meeting, first our Yes, We a products. a and spent for master honestly of cell creation bank. time the that shelf In thanks, the respect me hard we this off bank. then meetings lot we product to good like, comment iPS with Ed. cell it's of time. on had spent

to platform. our covering from days pre-IND application. think first first a did generate of our I products submission, good the we IND we product So I are of IPSC original an XX we two the mentioned, that job is intend in kind within the as meetings of But of totality it of

fairly landmark FDA's So the know on we should shortly IND this views submission.

Ted Tenthoff

through Dan. question it's you Correct. to new with you partnership CRISPR how lines? guys it these the And use then CRISPR potentially level taking to there? editing. next just and a And And for kind about MSK are of to going respect the to that cell What's add latest

Scott Wolchko

Sure. I'll that. let Dan handle

Dan Shoemaker

again for manufacturer during the up extensively tissues problem we've individual clone clonal FATE cell that NK And by the are, all serves products. around heterogeneity as activity. can end the IT point as we concern. on see the you're characterize like low I is process, here you're Yes, editing of of this But And significant there. potential Hey, when of been homogeneous activities where And I'm easiness to you're especially as incomplete challenges as translocations selecting get of off these you cell target like in we're clone you're off-target independent to an about lines. of levels or gene after batches where interesting billions safety of that, of our idea target and heterogeneity it's master editing deletions we going both approach with with platforms. a these what's targets. taking, that of starting a Ted. cells. Again at think Thanks the on highlight and field selection and Cool. this approach better different iPS that target get going billions time taken our serve and we batches really edited of bank even could thinking multi-gene cells true if And we

think I that anyway problem. think is keep our is that eye great really for on. very solution that our And clonal our I So approach important something to that heterogeneity a

Operator

you. Thank

comes with Our Robyn Karnauskas from next question Citi.

Your line is now open.

Robyn Karnauskas

have the around? you progress to until time you call to will what status Hi taking you unfold or If going able I disclose it's release when guys. the conversations some color IND question. finally or And the get you're is be having? was kind you disclosed would accepted And or guess earnings --the is could are just you it or about Thank can with how will like anything help for goals. we hear you understand press next an that? me you what of wait the

Scott Wolchko

Yes.

say. I it's to on as want the this of speculate feedback we from work submission. the too early think the I through what don't FDA to will nature be

We of an the of kind it extend first period allowance applications obviously have original of it's disclosed application, for beyond cell XX-day uncommon and in first to space. especially FDA that is not kind of therapy the

I certainly for is we're for planning allowance believe the Ultimately important clearance So company. and the an that. event

So certainly achieving we and announcing to that look forward that.

Robyn Karnauskas

then accelerated How additional we bit more the on Do learn ProTmune. ASH? patients, don't about When And little will patient? that you XX soon a these we Why happen? enrollment enrollment? the does have learn

Scott Wolchko

Yes.

So at the were ASH update, Phase-- administered is Phase subjects the the the ASH that update that we'll X from provide X ProTmune.

second all obviously as enrolled we have to will study. enroll up give subjects one XX where X an XX of you so the give the intending to we It's controlled quarter. a subjects. a Phase will progressed. update Phase The blinded of randomized subjects X the have those year end on And and will where we're And been subjects update

in for X we XXXX. data in Phase So are study a looking the

Operator

you. Thank

Capital from with Our Do question comes BMO next Markets. Kim,

open. now Your line is

Do Kim

afternoon questions. taking you, and my Thank thanks good for

can stable whether Phase of II a for and reached enrollment enrollment you have sort rate the of completion? general timeframe ProTmune say For study, provide you

Scott Wolchko

full have we quarter it rate, not I a for as we believe XX Yes, well we enrollment flat pace to or position at respect early enrollment significant subjects. say ASBMT. Obviously a mean of whether in that a disclosed the acceleration. is be to is at in that presented as were ASH hard both as acceleration that encouraging me It's second so stable represents I with discussed that XXXX. in a continues we that based on rate the data should even terrific

Do Kim

you. have and thank And from Phase design. important what the think the you good, on mean are II you Very from III about for when what would what learned you portion focusing for trial what the points the that Phase end I, Phase are

Scott Wolchko

is as comment on I Yes, an cumulative then comment I at Grade readout to XXX. we through that on mean I'll believe the incidence X X Grade Chris let continue that GvHD of day important well. acute

relapse. day certainly giving since fast is have high an designation the agents incidence severity patients at We can immunosuppressive systemically. typically with with acute and an GvHD rates treatment around of readout that effect that GvHD important It's XXX. of And absolutely track acute are done on of dose have cancer

we perspective XXX a that severity - end measuring perform in it's how the curative So foretell their within XX. can end acute outcomes what That secondary our of at outcomes from actively rates it point We're of is long-term ultimately are. curative is points, GvHD are our procedure, patients performed at day GvHD, one year. said, the key

So look outcome, from we cancer and is perspective key. of as relapse totality the certainly at survival and our

Do Kim

milestone And X for what that is question X you. the one and grand the thank the are is The dependant other FTXXX. received. installment Phase start is that the on milestones Phase last or funding that you installments on completion? What Great, last it,

Scott Wolchko

the milestone IND. believe I is based submission of the on last

Operator

Thank you.

question with from Our Wells Birchenough comes Jim next Securities. Fargo

Your line open. is now

Jim Birchenough

all the progress. taking for on thanks and congrats the guys, call Hi,

NK timelines the novel a then the and cell previously got here reference about follow-up. best XXX of I particularly that for here frame what's clearance. therapy on other for IND and like you've When of have space. a you this and is products think timeline reference potential frame Just precedent seen Thanks. What's FATE the the first-in-class in

Scott Wolchko

submission experience, which least three to think allowance relapse NKXXX about I was AML. point the at first submission mean from Yes, to refractory our was I NKXXX. I That would for months. in was

The with studies dimension NKXXX respect submission three being of NKXXX. for last submissions to in the submission different know was so last dimension were study. study there The three days. you allowed XX we're the As in

Jim Birchenough

want any allow first-in-class to And see the any may you - this FTXXX data is then the FTXXX extent suggestion you they FDA that safety that chance is the there at to or that, for to is may IND. Scott there preclinical look novel that and want do before

Scott Wolchko

no has of that. suggestion been There

they are think completely I unrelated.

Jim Birchenough

then I of as from of finally in that's to active And expect Do active? be How NKXXX kind guess think XXX? leading FTXXX just FTXXX? for indicator? expectations terms NKXXX, more should expect indicator What we for a whether NKXXX to as as for leading you data about the a

Scott Wolchko

different mean NKXXX mean, I donor that I derived obviously think products. they're I fundamentally products. is a

also So out, we're from different. with donor NKXXX pursuing with significantly heterogeneity on currently. like there different strategy that paradigm pursuing is with are derived that the get-go, a in checkpoint the all And patients the would is FTXXX multi-dose intended is which derived associated studies frankly, products, I inhibitors, we're it. than very be quite to and point planning combination

Jim Birchenough

GvHD When Got you about and are severe secondary one just without day to alive, patients and endpoint XXX. maybe it the ProTmune. relapse-free moderate one think who final at on of

the control the study? do ASH As what you to standard Phase from we the get of successful portion what result about care? in for think group What's would benchmark update from the you I, the the it of Phase expect II from will see expecting and

Scott Wolchko

at XX% patients living are with to It patients. space, of the transplantation a in successfully that wide But secondary hurdle. approximately Sure. either year range is died, patients active endpoint. respect this hematopoietic reported of a range of meet Unfortunately, the that of one most there XX% lot a - unfortunately, that somewhere fairly data is like GvHD. or relapsed to points with cell Only are in percent have

Operator

you. Thank

question next Nierengarten David comes Our Wedbush Securities. from with

Your open. line is

David Nierengarten

I slightly to Are In standard taking anticipate inhibitors, Herceptin planning XXX question. approved on explore is but inhibitors forward dose checkpoint checkpoint using you with than for about of I imagine you words, with slightly you do mechanism. presume to thanks side? or antibodies different if against Hi, dosing dosing one, more antibodies? it you're on on your other use standard the then the different Or thinking XXX. or Thanks. do going the given XXX, had and needing one doses other dosing

Scott Wolchko

The as doses. settings respect given those agents With as approved both where have agents approved those that antibodies. are or checkpoint we Sure. to will clinical be well trials proposed based inhibitors at monoclonal on and

Operator

question comes Reni from with next Benjamin James. Raymond Our

open. is line now Your

Reni Benjamin

Hi. Good for guess the NKXXX. its them, starting I of of been I DIMENSION notable you from both A mentioned taking questions. VOYAGE responses Thanks DIMENSION. I a mention guys. Scott, with APOLLO. just anything couple couple in off afternoon Didn't early and just NKXXX. to three mean that that finally any be just you haven't responses there tell doses in in Does yet increasing too all or maybe And to related will think and guess studies?

could you an failed write if remind me. to I upcoming down, at conference mentioned that which You

patients from in to data all reporting studies the do how each study you'll be think going about, three You're you many have?

Scott Wolchko

Okay.

feel So to questions hit I them there. in repeat a of apologize, And free don't if also couple I them.

the disclose disclosed data data disclosed simply historically not points we've in at mentioned, But we study not have So we historically data. because conferences. a I yet medical did DIMENSION

we've part so of as all update releasing conferences. three committed medical a is as NKXXX to study. November. to DIMENSION early been SITC we NKXXX provide at commit to data And data studies with did They're in across company And the already respect certainly an in

Reni Benjamin

And you'll just many patients worth think you sense how data it. give to them? can us of have Got as a you

Scott Wolchko

November in update an SITC at provide We'll

Reni Benjamin

Got it.

to Okay. FTXXX. Switching gears

this? gets of be are let's that evaluating going the updated. kinds IND the guys assuming to you What say look initial are Just trials are like? Where

Chris Storgard

here. Chris Hi,

of it have in patients are mentioned, population inhibitors in As to trial initial checkpoint I refractory the for with either the and on relapsed are approved the is checkpoint indications, combination inhibitor. using who or

study by initial X So be population. powered an the will Phase dose that's expansion. escalation; It initial

Reni Benjamin

Got it.

it's studies, focused not So or another. necessarily so all- on indication comer one an

Chris Storgard

It's inhibitors are in correct. That's populations where checkpoint currently approved.

Reni Benjamin

Got either potential you or ex-US. and maybe a about development thoughts your maybe little any ex-US regulatory talk strategies partnerships worldwide it. bit And regarding clinical can or

Scott Wolchko

Yes.

time, to We've United have to in With our the different point not platform opportunities. with had product this IPSC yet agencies So committed we those outside multiple meetings at States. respect ex-US. pioneering pursue

pursuing Although, we to opportunities are with partners. open in those collaboration

Reni Benjamin

off me, it one guys you're - clone And a when always that one Can just you of of a expanding for not guess not genomic? one talk doses, monitor then patients. one. of I've I you but could with then starting of And that about hundreds it's therapeutic key Okay. stability wondered thousands treat kind probably bit Dan how made little final batches and question stability? about the like genomics so this multi genomic to

Dan Shoemaker

great And clinic. that perform the you taking just at several that going optimally which one over have thing which we do characterization to dialogue it's then It's we as respect as in deletions to these developed passage we're numbers had as IPSC IND our tests banks just variety the ultimate our with the bank, and pay you a master the again discussion special genome question the into Yes. on comprehensive create all this cell tests number passes where characterization. with to right look that attention the then cell relevant Translocations, a therapies And degrees these edited fairly be perform to tell at pre strategy after products. master well your But of relative And banks test. FDA we with sufficient cell I to meetings. forward to could approaches it's very you is to of IPSC a but stability. perform a to important have question. been passage two the FDA when have and selected we've And another clones right working

Operator

any further showing Wolchko for would remarks. now back questions the time. over any I not like at Scott call to to I'm turn you. closing Thank this

Scott Wolchko

Thank you today's participating future. Thank very call. all you with in again look much. the speaking for you to in And forward we

Operator

day. gentlemen, And great in today's disconnect. and have Ladies does you conclude Everyone all This you thank may participating for program. today's a conference.

Fate Therapeutics (FATE) 6 Aug 182018 Q2 Earnings call transcript